UBS Group Lowers Owens & Minor (NYSE:OMI) Price Target to $13.00

Owens & Minor (NYSE:OMI) had its price objective dropped by analysts at UBS Group from $25.00 to $13.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target suggests a potential upside of 60.69% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on OMI. Citigroup lowered their price target on Owens & Minor from $21.00 to $18.50 and set a “buy” rating for the company in a report on Tuesday, November 5th. Robert W. Baird lowered their price target on Owens & Minor from $15.00 to $14.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Finally, Barclays lowered their price objective on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $16.79.

Owens & Minor Stock Down 1.2 %

OMI stock traded down $0.10 during midday trading on Thursday, hitting $8.09. 127,491 shares of the company’s stock were exchanged, compared to its average volume of 975,919. Owens & Minor has a 12-month low of $8.03 and a 12-month high of $28.35. The company has a current ratio of 1.09, a quick ratio of 0.45 and a debt-to-equity ratio of 2.11. The stock has a market capitalization of $623.82 million, a price-to-earnings ratio of -12.45, a price-to-earnings-growth ratio of 0.25 and a beta of 0.48. The firm has a 50 day moving average price of $13.05 and a 200-day moving average price of $13.95.

Insider Buying and Selling

In other Owens & Minor news, CFO Jonathan A. Leon sold 5,282 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $11.82, for a total transaction of $62,433.24. Following the completion of the transaction, the chief financial officer now owns 130,822 shares in the company, valued at approximately $1,546,316.04. The trade was a 3.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.59% of the stock is owned by company insiders.

Institutional Trading of Owens & Minor

Several institutional investors have recently modified their holdings of OMI. FMR LLC lifted its holdings in shares of Owens & Minor by 0.8% during the third quarter. FMR LLC now owns 11,564,624 shares of the company’s stock valued at $181,449,000 after purchasing an additional 90,862 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Owens & Minor by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,915,756 shares of the company’s stock worth $116,529,000 after acquiring an additional 107,092 shares in the last quarter. State Street Corp boosted its stake in shares of Owens & Minor by 2.6% during the 3rd quarter. State Street Corp now owns 3,064,547 shares of the company’s stock worth $48,083,000 after acquiring an additional 78,985 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Owens & Minor by 13.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,305,043 shares of the company’s stock worth $30,127,000 after acquiring an additional 276,807 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Owens & Minor by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,711,453 shares of the company’s stock valued at $26,858,000 after purchasing an additional 13,164 shares during the period. Institutional investors and hedge funds own 98.04% of the company’s stock.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.